Advancing Drug Development in Idiopathic Pulmonary Fibrosis: Tomorrow Is Now-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Advancing Drug Development in Idiopathic Pulmonary Fibrosis: Tomorrow Is Now

Published:2024-05-01 Issue:9 Volume:209 Page:1060-1062
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Khor Yet H.¹²³⁴⁵^ORCID,Ryerson Christopher J.⁶⁷

Affiliation:

1. Respiratory Research@Alfred

2. School of Translational MedicineMonash UniversityMelbourne, Victoria, Australia

3. Department of Respiratory and Sleep MedicineAustin HealthHeidelberg, Victoria, Australia

4. Institute for Breathing and SleepHeidelberg, Victoria, Australia

5. Faculty of MedicineUniversity of MelbourneMelbourne, Victoria, Australia

6. Department of MedicineUniversity of British ColumbiaVancouver, British Columbia, Canada

7. Centre for Heart Lung InnovationSt. Paul’s HospitalVancouver, British Columbia, Canada

Funder

National Health and Medical Research Council

Publisher

American Thoracic Society

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.202402-0381ED

Reference14 articles.

1. Fibrosis: from mechanisms to medicines

2. Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial

3. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis

4. Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP